Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Cell Therapy Development for Pancreatic Cancer

Cell Therapy Development for Pancreatic Cancer

Cell therapies can improve outcomes for pancreatic cancer patients through targeted therapeutic approaches. Alfa Cytology offers a full range of services, including cell line development, preclinical testing and detailed mechanistic studies, with the goal of developing effective cellular therapies for pancreatic cancer.

Overview of Cell Therapy for Pancreatic Cancer

Cell therapy represents a promising frontier in the fight against pancreatic cancer, characterized by its innovative approach to harnessing and manipulating cellular mechanisms to target and destroy cancerous cells. This therapeutic strategy leverages various types of cells, such as T-cells, NK cells, and stem cells, to enhance the body's natural immune response against tumors. By engineering these cells to recognize and attack pancreatic cancer cells more effectively, cell therapy offers a potential solution to overcoming the limitations of traditional treatments.

Fig. 1 Cellular immunotherapy for pancreatic cancer.Fig. 1 The next wave of cellular immunotherapies in pancreatic cancer. (Nhàn NTT, et al, 2023)

Several cell therapy drugs for pancreatic cancer are currently in various stages of development and clinical trials. Some of these include:

  • CAR-T Cells Targeting Mesothelin: Designed to target mesothelin-expressing pancreatic cancer cells, with ongoing trials evaluating their safety and efficacy.
  • CAR-T Cells Targeting Glypican-3: Aimed at targeting the glypican-3 antigen, a marker commonly overexpressed in pancreatic cancer cells.
  • TIL Therapy: Personalized TIL products derived from patient tumors, undergoing evaluation for their ability to induce remission in advanced pancreatic cancer.
  • Dendritic Cell-Based Vaccines: Utilizing dendritic cells to prime the immune system against pancreatic cancer-specific antigens, with ongoing research focusing on optimizing antigen presentation and vaccine efficacy.

Our Services

Alfa Cytology offers a one-stop solution for cell therapy development for pancreatic cancer, encompassing every stage from conceptual research to preclinical validation. The service includes cell line development, genetic modification, in vitro and in vivo testing, and detailed mechanistic studies. Our aim is to provide robust and reproducible cell therapy products tailored to the specific needs of pancreatic cancer research.

Cell Therapy Types We Can Develop

Stem Cell Therapy

Utilizing stem cells to promote tissue regeneration and immunomodulation.

CAR-T Cell Therapy

Involving the genetic modification of T cells to express chimeric antigen receptors targeting tumor antigens.

TCR-T Therapy

Employing T cells engineered to recognize specific tumor-associated antigens through T-cell receptors.

CAR-NK Therapy

Using genetically modified natural killer cells to target and destroy cancer cells.

TIL Therapy

Focusing on the isolation, expansion, and reinfusion of tumor-infiltrating lymphocytes.

CAR-iMac Therapy

Utilizing induced macrophages genetically engineered to target and eliminate tumor cells.

CIK Therapy

Combining T cells and natural killer cells to enhance anti-tumor activity.

Dendritic Cell Therapy

Using patient-derived dendritic cells to stimulate a targeted immune response against cancer cells.

Why Choose Us?

  • Customized Solutions: Tailored cell therapy development to meet specific research needs.
  • Cutting-Edge Technology: Utilization of the latest advancements in genetic engineering and cell therapy.
  • Comprehensive Support: Full-service support from initial research to preclinical validation.
  • Expertise: Extensive experience in pancreatic cancer research and cell therapy development.

By providing tailored solutions and utilising cutting-edge technology, our services are designed to improve the efficacy and specificity of cellular therapies. Alfa Cytology welcomes researchers and industry professionals to contact us to learn more about our cellular therapy development services and how they can be utilized to advance your research goals.

Reference

  1. Yeo D, et al. The next wave of cellular immunotherapies in pancreatic cancer. Molecular Therapy-Oncolytics. 2022, 24: 561-576.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.